Equities Analysts Set Expectations for TYRA FY2026 Earnings

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Equities researchers at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Tyra Biosciences in a report issued on Tuesday, September 22nd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.60) per share for the year, up from their prior forecast of ($2.86). HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.62) EPS, Q1 2027 earnings at ($0.56) EPS, Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.58) EPS and FY2027 earnings at ($2.27) EPS.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04).

Other equities analysts also recently issued reports about the stock. Oppenheimer reissued an “outperform” rating and issued a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research note on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $53.00 price objective on shares of Tyra Biosciences in a research note on Thursday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Jefferies Financial Group restated a “buy” rating and set a $42.00 target price on shares of Tyra Biosciences in a report on Wednesday, August 5th. Finally, Bank of America upped their price target on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.89.

Tyra Biosciences Stock Down 9.2%

Shares of TYRA opened at $23.23 on Thursday. Tyra Biosciences has a 52-week low of $12.40 and a 52-week high of $40.65. The stock has a market cap of $1.39 billion, a PE ratio of -9.68 and a beta of 0.73. The firm’s fifty day moving average is $27.19 and its two-hundred day moving average is $31.33.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Jupiter Topco LLC purchased a new stake in shares of Tyra Biosciences during the 2nd quarter valued at approximately $139,161,000. Janus Henderson Group PLC grew its position in Tyra Biosciences by 32.5% in the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock worth $148,867,000 after acquiring an additional 955,147 shares during the period. BlackRock Inc. acquired a new stake in Tyra Biosciences during the second quarter worth $96,841,000. 5AM Venture Management LLC increased its stake in Tyra Biosciences by 9.6% during the fourth quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock worth $27,060,000 after acquiring an additional 90,000 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in Tyra Biosciences in the first quarter valued at $24,222,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.